Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Orthopedic Oncologists Essential to Optimal QoL for Patients With Metastatic Bone Disease

January 30th 2020

R. Lor Randall, MD, discusses the referral challenges for orthopedic oncologists and the importance of improving quality of life for patients with metastatic bone disease.

Novel Surgical Technique Alleviates Adverse Events After Amputation in Patients With Cancer

January 30th 2020

Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.

P16, P21 Biomarkers Linked to Treatment Response in Osteosarcoma

January 29th 2020

C. Parker Gibbs, MD, discusses the research behind p16 and p21 as predictive biomarkers for treatment response in patients with osteosarcoma.

FDA Approves Tazemetostat for Epithelioid Sarcoma

January 24th 2020

The FDA has granted an accelerated approval to tazemetostat for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.

FDA Grants ADP-A2M4 RMAT Designation for Synovial Sarcoma

December 23rd 2019

The FDA has granted a Regenerative Medicine Advanced Therapy designation to ADP-A2M4 (MAGE-A4) as a treatment for patients with synovial sarcoma.

FDA Grants SP-2577 Fast Track Status for Ewing Sarcoma

December 23rd 2019

The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma.

ADP-A2M4 Shows Early Promising Clinical Activity in Synovial Sarcoma

December 20th 2019

Brian A. Van Tine, MD, PhD, discusses the results of a phase I study looking at the effects of ADP-A2M4 in patients with synovial sarcoma.

FDA Panel Supports Tazemetostat for Epithelioid Sarcoma

December 18th 2019

The FDA’s Oncologic Drugs Advisory Committee voted in favor of approving tazemetostat tablets as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.

FDA Schedules ODAC Meeting on Tazemetostat for Epithelioid Sarcoma

December 3rd 2019

The FDA has scheduled an Oncology Drugs Advisory Committee hearing for December 18, 2019, to discuss data supporting a new drug application for tazemetostat as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.

Dr. Alshaygy on Resection Margin for Dermatofibrosarcoma Protuberans

November 18th 2019

Ibrahim S. Alshaygy, MD, MSC, discusses research suggesting a smaller surgical resection margin for dermatofibrosarcoma protuberans.

Early Data Support Neoadjuvant Hypofractionated Radiotherapy in Soft Tissue Sarcoma

November 9th 2019

Joshua M. Lawrenz, MD, discusses the use of hypofractionated radiotherapy versus conventional radiotherapy in soft tissue sarcoma.

First-Ever Global Prospective Trial in Orthopedic Oncology Completes Accrual

November 5th 2019

Michelle Ghert, MD, FRCSC, discusses the PARITY and SAFETY trials and the future of research in orthopedic oncology.

Dr. Lawrenz on Hypofractionated Radiotherapy in Soft Tissue Sarcoma

November 5th 2019

Joshua M. Lawrenz, MD, discusses a study looking at hypofractionated radiotherapy in soft tissue sarcoma.

Ongoing Research Explores Novel Approaches in Soft Tissue Sarcoma

November 2nd 2019

Albert J. Aboulafia, MD, discusses advances in tenosynovial giant cell tumor and the early research and challenges in soft tissue sarcoma treatment.

Dr. Eward on FDA Approval of Pexidartinib in TGCT

October 30th 2019

William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.

Larger Surgical Margins Not Needed for Dermatofibrosarcoma Protuberans

October 29th 2019

Ibrahim S. Alshaygy, MD, MSC, discusses surgical developments in dermatofibrosarcoma protuberans and tenosynovial giant cell tumor.

Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue Sarcoma

October 25th 2019

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Intriguing Research Brings Hope to Orthopedic Oncology

October 22nd 2019

R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.

Neoadjuvant Immunotherapy Plus Radiation Shows Promise in Soft Tissue Sarcoma

October 22nd 2019

Vincent Y. Ng, MD, discusses what implications the NEXIS study could have in soft tissue sarcoma treatment and the next steps going forward.

Dr. Gibbs on Predicting Response to Treatment in Osteosarcoma

October 21st 2019

C. Parker Gibbs Jr., MD, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.